Goal Attainment and Physical Activity in People With Hemophilia A

计划入组 3 人 · 首次发布于 2024 年 7 月 31 日

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

计划入组 24 人 · 首次发布于 2024 年 8 月 30 日

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

计划入组 35 人 · 首次发布于 2025 年 4 月 24 日

Efanesoctocog alfa(Altuviiio, Altuvoct)

Efanesoctogog alfa

bifikafusp alfa + onfekafusp alfa

Alfa Wassermann SpA

Italy

Hospital General Puyo

Ecuador

Protalix Biotherapeutics

Israel

Hemophilia A and B Pipeline Advances with Novel Therapies in Clinical Trials

EU Approves Pfizer's Hympavzi as First Weekly Subcutaneous Treatment for Severe Hemophilia B

FDA Warning Letter to Genzyme Ireland Raises Supply Chain Alarm for Altuviiio Clinical Trials